Phathom Pharma Upgraded by Barclays to Overweight $18 Target
Barclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
Prioritizing financial planning is essential for young people aiming to build wealth. Learn the reasons to start your financial journey today.
27,102 articlesBarclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
A crypto veteran nicknamed the 'godfather crypto' argues Bitcoin could reach $1 million in time, yet warns that a nea...
As 2026 unfolds, the crypto market presents both opportunity and risk. This guide outlines the best cryptocurrencies ...
Coinbase warns possible weekend disruptions as it schedules a brief system upgrade for Saturday. Traders should expec...
When a major tech name drops, many investors feel the urge to retreat. Yet history shows that this tech stock down mo...
Rambus navigates a cooling memory-chip cycle that could weigh on margins even as AI infrastructure demand remains a k...
MSTU, a 2x daily ETF linked to MSTR, has endured a brutal period as the underlying stock and crypto markets gyrate, s...
Traders are turning to a wheel-style IBIT options strategy that converts Bitcoin's volatility into premium. The appro...
Analysts spotlight five dividend stocks yielding above 5% designed to provide steady income amid market volatility. T...
When chip stocks swing, choosing the right side matters. This guide weighs Nvidia vs AMD after the sell-off, with num...
AI-generated listing videos are reshaping real estate marketing, but new disclosures aim to curb misrepresentation. T...
Retail investors flock to a $50-priced ETF that looks like a safe cash substitute as rate expectations shift. Here’s ...